. . . . " "@en . . "Severe leukopenia with infection."@en . . . . . . . . . "* 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2] * 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2] * 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]"@en . . "Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity."@en . . "Mitoxantrone"@en . . . . "\"DrugSyn.org\":http://www.drugsyn.org/Mitoxantrone.htm"@en . . "78%"@en . . . . . . "75 hours"@en . . . . . "Mitoxantrona"@en . . . . "approved"@en . "An anthracenedione-derived antineoplastic agent. [PubChem]"@en . . . . "Humans and other mammals"@en . . . "Mitoxantronum"@en . . "1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione"@en . "* 1000 L/m2"@en . . "investigational"@en . . . . " "@en . . . "For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis"@en . "65271-80-9"@en . "Mitoxantrone"@en . . . "Poorly absorbed following oral administration"@en . . . . . . . . . . . . . "# Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16750460"@en . . . .